You are here

Novel Treatment for Breast Cancer: Truncated Galectin-3

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N/A
Agency Tracking Number: 1R43CA092801-01
Amount: $236,893.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2001
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
LAKESIDE MEDICAL CENTER 2645 OCEAN AVE, STE 302
SAN FRANCISCO, CA 94132
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 CONSTANCE JOHN
 () -
Business Contact
Phone: (415) 333-5570
Email: WWW.MANDALMED.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant):
Despite the available treatments breast cancer ranks second as the cause of
death from cancer in women primarily due to metastases of the primary tumor to
other sites in the body. We will extend our preliminary study of the
anticancer activity of recombinant human galectin-3 N-terminally truncated by
collagenase in an orthotopic mouse model of metastatic breast cancer.

We postulate that galectin-3 truncated by collagenase blocks the binding sites
for galectin-3 and prevent its cell crosslinking and other activities. We
will determine the in vivo efficacy of an analogous galectin-3 variant (delta
107) produced in E. coli and compare it with that of galectin-3 truncated
enzymatically. We will perform a dose-response analysis to firmly establish
the activity of the delta 107 variant, and address the optimal dose. We will
also test the anticancer activity of a slightly longer mutant of galectin-3.
A series of cell-based assays would be used to compare the in vitro activities
of the galectin-3 variants with intact galectin-3. Further development of
truncated galectin-3 as a clinical candidate for breast cancer would be the
focus of the Phase II research.
PROPOSED COMMERCIAL APPLICATION:
An estimated 40,800 Americans are expected to die of breast cancer this year. A
therapy that primarily acts to reduce metastasis could be effective in treating breast
cancer, especially early stage cancer. If galectin-3 has a reduced incidence of side
effects this would increase its attractiveness. The commercial potential of breast
cancer therapeutics is large.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government